MedWatch

Competition authority interferes with Takeda's deal with Danish Orifarm

Following 'thorough investigations' the Danish Competition and Consumer Authority has approved that Orifarm can take over a range of drugs and factories from Japanese Takeda. However, in return, the firm has to divest several products and rights.

Orifarm CEO Erik Sandberg | Photo: Orifarm / PR

The Danish Competition and Consumer Authority could not approve the whole of Danish supplier company Orifarm's billion-kroner deal with Japanese medical company from last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs